Article Information
History
- October 1, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Elizabeth M. Anderson1,
- Theresa Eilola1,
- Eileen Goodwin1,
- Marcus J. Bolton1,
- Sigrid Gouma1,
- Rishi R. Goel2,3,4,
- Mark M. Painter2,3,4,
- Sokratis A. Apostolidis2,3,5,
- Divij Mathew2,3,4,
- Debora Dunbar6,
- Danielle Fiore7,
- Amanda Brock8,
- JoEllen Weaver8,
- John S. Millar9,
- Stephanie DerOhannessian8,9,
- The UPenn COVID Processing Unit10,
- Allison R. Greenplate2,3,
- Ian Frank6,
- Daniel J. Rader8,9,
- E. John Wherry2,3,4,11 and
- Scott E. Hensley1,2,*
- 1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 2Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 3Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 4Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
- 5Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 6Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 7Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 8Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 9Department of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 11Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, PA 19104, USA
- ↵*Correspondence: hensley{at}pennmedicine.upenn.edu
Posted October 01, 2021.
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations
